BPC 157 and ipamorelin under FDA scrutiny Alex Keoskey posted on the topic LinkedIn BPC 157: Experimental Peptide Creates Risk for Athletes The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and clinics. With BPC 157, TB 500, and others under 503A review, questions around compounding, compliance, and what is When will the FDA reclassify BPC 157 to Category 1 Octagon AI